Pentoxyfylline

PreclinicalSmall molecule

PPatrick Northup, MD

Pentoxyfylline is one of 5 small molecule programs targeting Hepatorenal Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatorenal SyndromeActive, not recruiting

Hepatorenal SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hepatorenal Syndrome

#DrugCompanyPhaseTrials

Glypressin

MMallinckrodt

Approved

12 2

Letairis

Gilead

Phase 2

1 3

Sandostatin

Sun Pharma

Preclinical

2 4

Nor-Epinephrine

NNational Hepatology & Tropical Medicine Research Institute

Preclinical

1 5

Pentoxyfylline

PPatrick Northup, MD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatorenal Syndrome1 trial

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Terminated·PPatrick Northup, MD·N/A·NCT02123576·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pentoxyfylline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentoxyfylline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentoxyfylline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Patrick Northup, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPatrick Northup, MD

Pentoxyfylline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatorenal Syndrome1 trial

References

Drug Info

Quick Facts

Related News